Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- PMS Activities Put Additional Burden on Doctors
October 5, 2009
- Price Gaps Remain Unchanged for Drugs Priced by Similar Efficacy Comparison Method
October 5, 2009
- Fixed-Dose Combination Drugs Should Be Priced at 10-30% of the Sum of Prices of Combined Drugs: Korosho
October 5, 2009
- Term of Office to Expire for 6 of 7 Chuikyo Members Representing Healthcare Providers
October 5, 2009
- Drug Wholesalers Should Compete on the Strength of Their General Capability: Mr Kinoshita
September 28, 2009
- Promotional Activities for Pariet Have Greatest Impact on Prescription: Survey
September 28, 2009
- Cravit Remains No. 1 on Both HP and GP Markets: Rep Track Survey
September 28, 2009
- Support from Drug Makers Influence Doctors Prescription
September 28, 2009
- BUSINESS NEWS IN BRIEF
September 28, 2009
- SEMINAR
September 28, 2009
- Fundamentally Review Budget Formation Process: Mr Hatoyama
September 28, 2009
- 24-Year-Old Woman without Underlying Disease Dies due to New-Type Flu
September 28, 2009
- METI to Support Drug Development Technology
September 28, 2009
- NEW PRODUCTS
September 28, 2009
- JPMA to Stress Importance of Pharma Industry to New Govt
September 28, 2009
- First Biosimilars Priced at 70% of Prices of Original Products
September 28, 2009
- REGULATORY NEWS IN BRIEF
September 28, 2009
- Sales of Ethical Drugs Up 5.3% in July: Crecon
September 28, 2009
- Akira Nagatsuma Appointed Health Minister
September 28, 2009
- Novo Nordisk to Develop Worlds First Oral GLP-1 Analogue, Insulin
September 28, 2009
ページ
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…